Company profile
Pulmatrix, Inc.
NASDAQ: PULM · Healthcare · Biotechnology
#658 of 1,418 Healthcare companies by revenue52nd-percentile growth
EA Score
46DFH 38DQ 56GM 58SS 34
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, disclosure history · ↓ Piotroski F, workforce scale
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$5.2M
Employees
2
as of 2026-08-23
Market cap
$5.5M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$7.8M$7.8M2024
Net income-$5.2M-$5.2M2025
Operating income-$5.2M-$5.2M2025
Total assets$4.1M$4.1M2025
Liabilities$329.0k$329.0k2025
Equity$3.8M$3.8M2025
Revenue trend
FY2017 – FY2024 · USD
FY17
FY18
FY20
FY20
FY21
FY22
FY23
FY24
Revenue by segment
Filed disclosures · FY2020
By product
Toxicology Study Costs100%
By geography
Not disclosed.
The read
What is Pulmatrix, Inc.’s revenue?
Pulmatrix, Inc. booked $7.8M in FY2024 revenue, growing 7.0% year over year — about the middle of the pack among Healthcare companies we track, at a -66.1% net margin.
Peers · Healthcare
Coya Therapeutics, Inc.48DCogent Biosciences, Inc.48DAclaris Therapeutics, Inc.47DCrinetics Pharmaceuticals, Inc.53DBolt Biotherapeutics, Inc.39DBeyond Air, Inc.42DNeighbors
Middlesex →Key facts
CEOPeter Ludlum
SectorHealthcare
IndustryBiotechnology
HeadquartersLexington, MA
ExchangeNASDAQ: PULM
Employees2
IPO date2014-03-21
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.